JPWO2023111311A5 - - Google Patents
Info
- Publication number
- JPWO2023111311A5 JPWO2023111311A5 JP2024536163A JP2024536163A JPWO2023111311A5 JP WO2023111311 A5 JPWO2023111311 A5 JP WO2023111311A5 JP 2024536163 A JP2024536163 A JP 2024536163A JP 2024536163 A JP2024536163 A JP 2024536163A JP WO2023111311 A5 JPWO2023111311 A5 JP WO2023111311A5
- Authority
- JP
- Japan
- Prior art keywords
- seq
- isoform
- vlcdr2
- vhcdr2
- vlcdr3
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Pending
Links
Applications Claiming Priority (7)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| EP21215028 | 2021-12-16 | ||
| EP21215028.8 | 2021-12-16 | ||
| EP22164796 | 2022-03-28 | ||
| EP22164796.9 | 2022-03-28 | ||
| EP22207926.1 | 2022-11-16 | ||
| EP22207926 | 2022-11-16 | ||
| PCT/EP2022/086452 WO2023111311A1 (en) | 2021-12-16 | 2022-12-16 | Discernible cell surface protein variants of cd117 for use in cell therapy |
Publications (3)
| Publication Number | Publication Date |
|---|---|
| JP2024546996A JP2024546996A (ja) | 2024-12-26 |
| JPWO2023111311A5 true JPWO2023111311A5 (https=) | 2025-12-23 |
| JP2024546996A5 JP2024546996A5 (https=) | 2025-12-23 |
Family
ID=84981434
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2024536163A Pending JP2024546996A (ja) | 2021-12-16 | 2022-12-16 | 細胞療法に使用するためのｃｄ１１７の識別可能な細胞表面タンパク質変異体 |
Country Status (10)
| Country | Link |
|---|---|
| US (1) | US20250057951A1 (https=) |
| EP (1) | EP4448573A1 (https=) |
| JP (1) | JP2024546996A (https=) |
| KR (1) | KR20240115920A (https=) |
| AU (1) | AU2022409748A1 (https=) |
| CA (1) | CA3240527A1 (https=) |
| IL (1) | IL313568A (https=) |
| MX (1) | MX2024007317A (https=) |
| WO (1) | WO2023111311A1 (https=) |
| ZA (1) | ZA202405110B (https=) |
Families Citing this family (3)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| EP4540287A1 (en) * | 2022-06-20 | 2025-04-23 | CRISPR Therapeutics AG | Chimeric antigen receptor specific to cd117 |
| KR20250034296A (ko) * | 2022-07-07 | 2025-03-11 | 씨메이오 테라퓨틱스 아게 | Cd117을 표적화하는 항체 |
| WO2025231071A1 (en) * | 2024-05-01 | 2025-11-06 | Beam Therapeutics Inc. | Compositions and methods for cell conditioning |
Family Cites Families (14)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| DK0578774T3 (da) | 1991-04-05 | 1999-04-26 | Univ Washington | Monoklonale antistoffer mod stamcellefaktor-receptorer |
| TWI395754B (zh) | 2006-04-24 | 2013-05-11 | Amgen Inc | 人類化之ｃ-ｋｉｔ抗體 |
| WO2015050959A1 (en) | 2013-10-01 | 2015-04-09 | Yale University | Anti-kit antibodies and methods of use thereof |
| US10786578B2 (en) | 2014-08-05 | 2020-09-29 | Novartis Ag | CKIT antibody drug conjugates |
| US11499168B2 (en) | 2016-04-25 | 2022-11-15 | Universitat Basel | Allele editing and applications thereof |
| AU2017355218B2 (en) | 2016-11-02 | 2024-02-22 | Universität Basel | Immunologically discernible cell surface variants for use in cell therapy |
| SG11201907870VA (en) | 2017-02-28 | 2019-09-27 | Vor Biopharma Inc | Compositions and methods for inhibition of lineage specific proteins |
| TWI687227B (zh) * | 2017-10-03 | 2020-03-11 | 生倍科技股份有限公司 | 用於t細胞免疫療法之組合及其用途 |
| CA3079215A1 (en) * | 2017-10-24 | 2019-05-02 | Magenta Therapeutics, Inc. | Compositions and methods for the depletion of cd117+ cells |
| CA3079897A1 (en) | 2017-10-24 | 2019-05-02 | Magenta Therapeutics, Inc. | Compositions and methods for the depletion of cd117+ cells |
| US12378318B2 (en) * | 2018-08-08 | 2025-08-05 | Dragonfly Therapeutics, Inc. | Proteins binding NKG2D, CD16 and a tumor-associated antigen |
| CN119684457A (zh) | 2018-11-26 | 2025-03-25 | 四十七有限责任公司 | 针对c-kit的人源化抗体 |
| JP2022529727A (ja) * | 2019-04-24 | 2022-06-23 | マジェンタ セラピューティクス インコーポレイテッド | Ａｎｔｉ－ｃｄ１１７ とその使用 |
| US20230017979A1 (en) | 2019-08-29 | 2023-01-19 | Beam Therapeutics Inc. | Compositions and methods for non-toxic conditioning |
-
2022
- 2022-12-16 WO PCT/EP2022/086452 patent/WO2023111311A1/en not_active Ceased
- 2022-12-16 JP JP2024536163A patent/JP2024546996A/ja active Pending
- 2022-12-16 MX MX2024007317A patent/MX2024007317A/es unknown
- 2022-12-16 EP EP22843648.1A patent/EP4448573A1/en active Pending
- 2022-12-16 KR KR1020247023745A patent/KR20240115920A/ko active Pending
- 2022-12-16 AU AU2022409748A patent/AU2022409748A1/en active Pending
- 2022-12-16 US US18/719,780 patent/US20250057951A1/en active Pending
- 2022-12-16 IL IL313568A patent/IL313568A/en unknown
- 2022-12-16 CA CA3240527A patent/CA3240527A1/en active Pending
-
2024
- 2024-06-28 ZA ZA2024/05110A patent/ZA202405110B/en unknown
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| JP7379561B2 (ja) | キメラ抗原及びｔ細胞受容体、並びに使用方法 | |
| CN112534052B (zh) | 全新il-21前药及使用方法 | |
| CN105189562B (zh) | Il-15异源二聚体蛋白及其用途 | |
| CN106459213B (zh) | 修饰的j链 | |
| JP2026016505A (ja) | Ｉｌ－１０バリアント分子ならびに炎症性疾患および腫瘍を処置する方法 | |
| JP6731403B2 (ja) | 免疫応答およびがん治療の増強に使用するための組成物および方法 | |
| JP7530904B2 (ja) | 特異的結合性分子 | |
| CN114341189A (zh) | 全新il-15前药及其应用 | |
| WO2019080872A1 (zh) | 阻断pd-1/pd-l1信号传导途径且活化t细胞的融合蛋白及其用途 | |
| TW201842937A (zh) | 免疫結合物 | |
| WO2019062642A1 (zh) | 靶向pd-1或pd-l1且靶向vegf家族的双靶向融合蛋白及其用途 | |
| WO2018036473A1 (zh) | 抗ctla4-抗pd-1双功能抗体、其药物组合物及其用途 | |
| PL189696B1 (pl) | Koniugat, kompozycja obejmująca koniugat i zastosowanie koniugatu | |
| JP2022509017A (ja) | 抗ｐｔｋ７免疫細胞癌療法 | |
| CN116323667A (zh) | 结合PSMA和γ-δT细胞受体的抗体 | |
| TW201623330A (zh) | Ｉｌ－２１抗體 | |
| CN115397515A (zh) | 人抗cd33抗体和其用途 | |
| WO2022223001A1 (zh) | 双特异性多功能融合多肽 | |
| WO2022152186A1 (zh) | 靶向cd5的全人源单域串联嵌合抗原受体(car)及其应用 | |
| JP2023516195A (ja) | Ｃ１９ ｃ３８二特異性抗体 | |
| TW202440636A (zh) | Ｃｄ１９／ｃｄ３８多特異性抗體 | |
| CN115279412A (zh) | 偶联脂肪酸分子的抗体及其用途 | |
| TW202132341A (zh) | 以hla-a2/wt1 x cd3雙特異性抗體及來那度胺（lenalidomide）治療癌症 | |
| WO2023020537A1 (zh) | 一种双特异性抗体及其用途 | |
| US20230218669A1 (en) | Augmenting antigen-negative cell death in antigen-targeted immunotherapies |